Gansevoort et al. (54) investigated, in addition to validating baseline copeptin correlation with the rate of future ADPKD progression, whether baseline copeptin level and treatment-induced change in copeptin levels correlate with tolvaptan treatment efficacy in 1,280 ADPKD patients. This evidence concerns the gene AVP and autosomal dominant polycystic kidney disease.